200 related articles for article (PubMed ID: 36171475)
1. Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model.
Stannard HL; Mifsud EJ; Wildum S; Brown SK; Koszalka P; Shishido T; Kojima S; Omoto S; Baba K; Kuhlbusch K; Hurt AC; Barr IG
Commun Biol; 2022 Sep; 5(1):1026. PubMed ID: 36171475
[TBL] [Abstract][Full Text] [Related]
2. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
Farrukee R; Gunalan V; Maurer-Stroh S; Reading PC; Hurt AC
J Virol; 2022 Aug; 96(15):e0091822. PubMed ID: 35867563
[TBL] [Abstract][Full Text] [Related]
3. Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.
Abed Y; Pizzorno A; Bouhy X; Rhéaume C; Boivin G
J Virol; 2014 Feb; 88(3):1652-8. PubMed ID: 24257597
[TBL] [Abstract][Full Text] [Related]
4. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
Hamelin ME; Baz M; Bouhy X; Beaulieu E; Dubé K; Mallett C; Boivin G
Antivir Ther; 2011; 16(5):775-9. PubMed ID: 21817200
[TBL] [Abstract][Full Text] [Related]
5. Impact of Baloxavir Resistance-Associated Substitutions on Influenza Virus Growth and Drug Susceptibility.
Hickerson BT; Petrovskaya SN; Dickensheets H; Donnelly RP; Ince WL; Ilyushina NA
J Virol; 2023 Jul; 97(7):e0015423. PubMed ID: 37404185
[TBL] [Abstract][Full Text] [Related]
6. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
7. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
[TBL] [Abstract][Full Text] [Related]
8. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
9. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses.
Abed Y; Pizzorno A; Bouhy X; Boivin G
PLoS Pathog; 2011 Dec; 7(12):e1002431. PubMed ID: 22174688
[TBL] [Abstract][Full Text] [Related]
10. Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.
Wong DD; Choy KT; Chan RW; Sia SF; Chiu HP; Cheung PP; Chan MC; Peiris JS; Yen HL
J Virol; 2012 Oct; 86(19):10558-70. PubMed ID: 22811535
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors.
Kiso M; Yamayoshi S; Kawaoka Y
J Antimicrob Chemother; 2023 Jul; 78(7):1649-1657. PubMed ID: 37209424
[TBL] [Abstract][Full Text] [Related]
13.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
14. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets.
Duan S; Boltz DA; Seiler P; Li J; Bragstad K; Nielsen LP; Webby RJ; Webster RG; Govorkova EA
PLoS Pathog; 2010 Jul; 6(7):e1001022. PubMed ID: 20686654
[TBL] [Abstract][Full Text] [Related]
15. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
[TBL] [Abstract][Full Text] [Related]
16. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Lee LYY; Zhou J; Frise R; Goldhill DH; Koszalka P; Mifsud EJ; Baba K; Noda T; Ando Y; Sato K; Yuki AI; Shishido T; Uehara T; Wildum S; Zwanziger E; Collinson N; Kuhlbusch K; Clinch B; Hurt AC; Barclay WS
PLoS Pathog; 2020 Apr; 16(4):e1008395. PubMed ID: 32294137
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.
Pizzorno A; Abed Y; Rhéaume C; Bouhy X; Boivin G
Antimicrob Agents Chemother; 2013 Apr; 57(4):1784-9. PubMed ID: 23357777
[TBL] [Abstract][Full Text] [Related]
18. Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Abed Y; Tu V; Carbonneau J; Checkmahomed L; Venable MC; Fage C; Marie-Ève-Hamelin ; Dufresne SF; Kobinger G; Boivin G
Antiviral Res; 2018 Nov; 159():26-34. PubMed ID: 30219318
[TBL] [Abstract][Full Text] [Related]
19. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
20. Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
Abed Y; Pizzorno A; Bouhy X; Boivin G
Antiviral Res; 2015 Feb; 114():57-61. PubMed ID: 25512229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
